IKT Inhibikase Therapeutics
- 1.3672
- +0.0072+0.53%
Inhibikase Therapeutics News
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase
Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock.
MRIN, WISA and SMFL Among Mid-day Movers
Inhibikase Therapeutics Files to Sell Common Stock, Warrants
Inhibikase Therapeutics Updates Shareholders on Future Plans
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
Inhibikase Therapeutics Announces Apr. 5 Pre-IND Meeting With FDA For IkT-001Pro In Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Apr. 5 Pre-IND Meeting With FDA For IkT-001Pro In Pulmonary Arterial Hypertension
Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress
Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
Earnings Call Summary | Inhibikase Therapeutics(IKT.US) Q4 2023 Earnings Conference
The following is a summary of the Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript:Financial Performance:Inhibikase Therapeutics reported a net loss of $19.0 million for 2023, slig
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.85) by 24.71 percent. This is a 37.25 percent increase over losses
Inhibikase Therapeutics GAAP EPS of -$3.57 Misses by $0.82, Revenue of $0.26M In-line
Inhibikase Therapeutics FY23 EPS $(3.57); Cash Position $13.3M As Of Dec. 31
Inhibikase Therapeutics FY23 EPS $(3.57); Cash Position $13.3M As Of Dec. 31
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
04:19 PM EDT, 03/27/2024 (MT Newswires) -- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target
HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics with a Buy and maintains $27 price target.
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Maintains $27 Price Target
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics with a Buy and maintains $27 price target.
Inhibikase Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 1155.81% HC Wainwright & Co. $27 → $27 Maintains Buy 08/15/2023 1155.81% HC Wainwright & Co. →
Analysis
Price Target
No Data
